Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Halperin

Dermatology New York, NY Medical Doctor

NPI 1487727541 CMS profile 519534

115 E 61St St, New York, NY 10021

Open in the dashboard

General payments

$11,472

757 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Halperin of New York, NY is reported in the CMS Open Payments database as having received $11,472 across 757 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,109 137
2024 General $1,574 94
2023 General $1,934 113
2022 General $1,780 126
2021 General $1,547 92
2020 General $1,136 81
2019 General $1,392 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Halperin
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Peter Halperin were reported at $2,109. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Peter Halperin Dermatology median Middle half National median
2019 $1,392 $454 $129–$1,240 $163
2020 $1,136 $235 $81–$756 $114
2021 $1,547 $377 $108–$1,108 $132
2022 $1,780 $514 $143–$1,391 $149
2023 $1,934 $607 $159–$1,674 $160
2024 $1,574 $751 $204–$1,903 $164
2025 $2,109 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,771 163 payments
  2. Janssen Biotech, Inc. $1,261 84 payments
  3. Genzyme Corporation $1,254 57 payments
  4. Galderma Laboratories, L.P. $942 70 payments
  5. Pfizer Inc. $779 61 payments
  6. Lilly USA, LLC $587 35 payments
  7. Incyte Corporation $510 30 payments
  8. UCB, Inc. $507 29 payments
  9. LEO Pharma Inc. $481 32 payments
  10. Dermavant Sciences, Inc. $411 30 payments
  11. Other $2,969 166 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,946 747 payments
  2. Education $526 10 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $1,306 59 payments
  2. TREMFYA $1,237 82 payments
  3. SKYRIZI $751 77 payments
  4. TALTZ $587 35 payments
  5. RINVOQ $545 39 payments
  6. OPZELURA $510 30 payments
  7. EUCRISA $460 42 payments
  8. VTAMA $433 32 payments
  9. Otezla $350 17 payments
  10. CIBINQO $337 20 payments
  11. Other $6,449 392 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,140

Median for Dermatology: 534

Drug cost

$365,710

Median for Dermatology: $67,151

Branded share of claims

12.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 59 $231,442
Otezla Apremilast Brand 15 $72,449
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 34 $21,496
Calcipotriene Generic 98 $8,388
Metronidazole Generic 77 $6,703
Fluorouracil Generic 121 $5,967
Ketoconazole Generic 120 $4,409
Ciclopirox Generic 73 $2,845
Clobetasol Propionate Generic 48 $2,627
Mometasone Furoate Generic 106 $1,925

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$109,065

Medicare's payments for the services billed

Medicare patients

1,029

Average age 80

Services billed

2,722

524 women, 505 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 48%
Osteoporosis 29%
Ischemic heart disease 27%
Cancer 24%
Diabetes 19%
Atrial fibrillation 19%
Depression 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$250 — —
VTAMA
$188 — —
SKYRIZI
$168 — —
Bimzelx
$164 — —
DUPIXENT
$154 59 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

757 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record